| Ytd | 30.37% | |
| 1y | -22.28% |
| Open | 2.75 | Prev Close | 2.77 | Low | 2.69 | High | 2.83 | Mkt Cap | 44.78M |
| Vol | 466.16K | Avg Vol | 2.02M | EPS | -1.49 | P/E | -1.87 | Forward P/E | -2.23 |
| Beta | -0.46 | Short Ratio | 13.35 | Inst. Own | 42.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 04-28 | Earning | 08-12 | 50-d Avg | 2.70 | 200-d Avg | 2.52 | 1yr Est | 3.40 |
VERU News
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to alrea
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim ana
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on tr
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharm
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average du
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during tra
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average dur
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bo
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both sma
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during tra
Investors are prepping for this week's earnings reports which include homebuilders, several appa
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly e
On Wednesday, 311 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
On Wednesday, 220 stocks hit new 52-week lows.
On Monday, 76 companies set new 52-week lows.
On Friday, 93 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Thursday's session saw 337 companies set new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
On Friday, 497 companies set new 52-week lows.
Companies Reporting Before The Bell • AstraZeneca (NASDAQ:AZN) is expected to report quarterly earn
Gainers